{"id":"NCT01778062","sponsor":"Novartis Pharmaceuticals","briefTitle":"Indacaterol EfectIveness In COPD Patients With Tuberculosis History","officialTitle":"A Phase Ⅲb, Multicenter, Double-blind, Randomized, Controlled Trial, to Assess the Efficacy and Safety of Indacaterol (150㎍ o.d.) vs. Placebo, in Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-02","primaryCompletion":"2014-09","completion":"2014-09","firstPosted":"2013-01-29","resultsPosted":"2015-09-18","lastUpdate":"2015-10-23"},"enrollment":136,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis"],"interventions":[{"type":"DRUG","name":"Indacaterol","otherNames":[]},{"type":"DRUG","name":"Control","otherNames":["Placebo"]}],"arms":[{"label":"Indacaterol","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This clinical study will assess efficacy and safety of indacaterol (150㎍ o.d.) in patients with Chronic Obstructive Pulmonary Disease (COPD) with destroyed lung by tuberculosis.","primaryOutcome":{"measure":"Trough Forced Expiratory Volume in One Second Change","timeFrame":"8 week","effectByArm":[{"arm":"Indacaterol","deltaMin":0.08,"sd":0.16},{"arm":"Placebo","deltaMin":-0.06,"sd":0.1}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"19 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":19},"locations":{"siteCount":13,"countries":["South Korea"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":68},"commonTop":["Upper respiratory tract infection","COPD Exacerbation","Nasopharyngitis"]}}